Trial Profile
Study on the maintenance of apatinib and the administration of apatinib in patients with primary liver cancer after TACE treatment
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Aug 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 07 Aug 2018 New trial record